Logo of Mesoblast (ASX:MSB)Latest Mesoblast (ASX:MSB) News

Page 4
Page 4 of 5

FDA Signals Support for Mesoblast’s Rexlemestrocel-L in Chronic Back Pain and Opioid Reduction

Mesoblast has received encouraging feedback from the FDA on its cell therapy rexlemestrocel-L, showing meaningful pain relief and potential opioid use reduction in chronic low back pain patients. The company’s ongoing Phase 3 trial aims to confirm these benefits and advance regulatory approval.
Ada Torres
19 Jan 2026

Mesoblast’s Ryoncil Sales Soar 60% as New $125M Facility Boosts Growth

Mesoblast Limited reports a 60% jump in Ryoncil sales for the December quarter, underpinned by a new $125 million financing facility that strengthens its balance sheet and strategic flexibility.
Ada Torres
9 Jan 2026

Mesoblast Secures US$125M Credit Line, Slashes Debt Costs and Boosts Flexibility

Mesoblast has refinanced its senior debt with a new US$125 million, five-year credit facility that lowers borrowing costs and preserves key assets, positioning the company for strategic growth.
Ada Torres
30 Dec 2025

Independent Study Finds Mesoblast’s Remestemcel-L Outperforms Ruxolitinib in SR-aGvHD

An independent meta-analysis presented at the ASH Annual Meeting reveals Mesoblast’s remestemcel-L achieves superior remission rates and safety outcomes compared to ruxolitinib in treating steroid-refractory acute graft-versus-host disease.
Ada Torres
12 Dec 2025

Mesoblast Projects 37% Revenue Surge on Ryoncil Sales in Q4 2025

Mesoblast Limited forecasts a significant jump in quarterly revenue, driven by strong sales of its FDA-approved cell therapy Ryoncil. The company’s latest update highlights robust growth and ongoing expansion in inflammatory disease treatments.
Ada Torres
25 Nov 2025

Mesoblast’s RYONCIL Surges with FDA Nod and $30M Quarterly Revenue

Mesoblast has achieved a landmark FDA approval for RYONCIL, the first allogeneic mesenchymal stromal cell therapy, driving strong commercial momentum and advancing a robust pipeline targeting inflammatory diseases.
Ada Torres
25 Nov 2025

Mesoblast Prepares FDA Talks on Rexlemestrocel-L’s Opioid Cessation Promise

Mesoblast is set to meet the FDA in December to discuss compelling Phase 3 data showing its cell therapy rexlemestrocel-L may significantly reduce opioid use in chronic low back pain patients. This meeting could mark a pivotal step in addressing the US opioid crisis through innovative regenerative medicine.
Ada Torres
5 Nov 2025

Mesoblast’s Ryoncil Revenues Surge 69% Following Key FDA and CMS Milestones

Mesoblast Limited reports a 69% jump in net revenues from its pioneering cell therapy Ryoncil in Q1 FY2026, propelled by expanded physician adoption and new reimbursement pathways. The company also secures convertible note funding and plans pivotal adult trials.
Ada Torres
20 Oct 2025

Mesoblast’s Ryoncil Sales Jump 66% After FDA Approval and CMS Reimbursement

Mesoblast Limited reports a robust 66% increase in Ryoncil revenues for Q2 2025, driven by strong market adoption and new Medicare reimbursement codes.
Ada Torres
7 Oct 2025

Mesoblast Secures US$50M Convertible Note Option to Boost Capital Structure

Mesoblast has entered agreements to issue up to US$50 million in convertible notes, aiming to strengthen its capital base and support pipeline growth, pending shareholder approval.
Ada Torres
4 Sept 2025

Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge Amid FDA Milestone

Mesoblast Limited marked a transformative year with FDA approval and commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, driving a 191% jump in cell therapy revenues. The company is now poised to expand its footprint in inflammatory diseases with multiple clinical trials and label extensions underway.
Ada Torres
29 Aug 2025

Mesoblast’s Ryoncil Launch Sparks 191% Revenue Surge in FY2025

Mesoblast reports a strong FY2025 financial performance driven by the commercial launch of Ryoncil, the first FDA-approved mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease in children. The company is advancing multiple clinical programs targeting inflammatory diseases, heart failure, and chronic low back pain.
Ada Torres
29 Aug 2025